Renal Tumor Ablation Via the Liver Is Safe, Effective

Share this content:
Researchers show that ultrasound-guided radiofrequency ablation is technically feasible.
Researchers show that ultrasound-guided radiofrequency ablation is technically feasible.

Percutaneous ultrasound-guided transhepatic radiofrequency ablation (RFA) of renal tumors is technically feasible and oncologically efficacious, according to investigators. It also is associated with a low complication rate.

“The transhepatic approach may allow safe ablation of renal tumors that would otherwise be difficult to treat,” a team at Mayo Clinic in Rochester, Minn., led by Thomas D. Atwell, MD, concluded in a paper published in Cardiovascular and Interventional Radiology (2014;37:508-512)..

Dr. Atwell and his colleagues pointed out that some renal tumors are in locations not easily accessed directly by conventional approaches. “When treating masses in the right kidney, overlying bowel or inflated lung can limit safe introduction of the RFA applicator,” they explained. “In addition, respiratory-related motion of a renal mass may make accurate applicator placement challenging.”

Because of the anatomic relationship of the liver and right kidney, they noted, a percutaneous transhepatic approach can be used to place the RFA applicator, obviating concerns related to bowel and lung. “Using real-time ultrasound guidance, the proceduralist can account for respiratory motion, allowing precise applicator placement,” they stated.

In a study, Dr. Atwell's group used transhepatic renal RFA to treat 19 tumors in 18 patients. The tumors had a median maximal diameter of 1.9 cm. No major complications developed during any of the procedures. No hepatic tumor seeding was identified during imaging follow-up.

Imaging follow-up with computed tomography or magnetic resonance imaging was available for 16 patients at a median of 28 months. A single technique failure occurred in the treatment of a 3.0 cm tumor.

The study had some limitations, including a small study population and relatively short follow-up for oncologic outcomes, the researchers stated.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs